New drug tested for Tough-to-Treat blood cancer
NCT ID NCT04184050
Summary
This is an early-stage study to test the safety of a new drug called HPN217 (or MK-4002) for people with multiple myeloma that has come back or stopped responding to other treatments. Researchers will give increasing doses to about 100 participants to find the highest dose that is safe and to see how the drug moves through the body. The main goal is to understand the side effects and determine a safe dose for future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234, United States
-
Centre Hospitalier Universitaire De Nantes
Nantes, 44093, France
-
Centre Hospitalier Universitaire de Poitiers
Poitiers, 86021, France
-
Hospital Universitario Fundacion Jimenez Diaz (UAM-FJD)
Madrid, 28040, Spain
-
Josep Carreras Leukaemia Research Institute
Barcelona, 08916, Spain
-
Mayo Clinic Arizona
Phoenix, Arizona, 85054, United States
-
OHSU
Portland, Oregon, 97239, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
-
The University of Kansas Cancer Center
Fairway, Kansas, 66205, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
University of Rochester James P Wilmot Cancer Institute
Rochester, New York, 14642, United States
-
University of Washington - Seattle Cancer Center Alliance
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.